Bevacizumab plus chemotherapy continued beyond progression in patients with type II endometrial cancer previously treated with bevacizumab plus chemotherapy: A case report

  • Authors:
    • Emi Sato
    • Kentaro Nakayama
    • Kohei Nakamura
    • Tomoka Ishibashi
    • Hiroshi Katagiri
    • Masako Ishikawa
    • Satoru Kyo
  • View Affiliations

  • Published online on: July 13, 2017     https://doi.org/10.3892/mco.2017.1316
  • Pages:391-394
0

Abstract

The prognosis of patients with recurrent/persistent endometrial cancer, particularly type II cancer, remains poor, and effective treatment has not yet been established. We herein present the case of a patient with recurrent type II endometrial cancer who received bevacizumab + chemotherapy continued beyond progression, after previously receiving bevacizumab + chemotherapy. This patient experienced recurrence after first‑ and second‑line adjuvant chemotherapy followed by modified radical hysterectomy and she was administered bevacizumab + paclitaxel + carboplatin therapy. After six cycles of treatment, all metastatic lesions shrunk, indicating partial response. The patient next received single‑agent bevacizumab as maintenance therapy. After 12 cycles of bevacizumab monotherapy, disease progression was detected; therefore, combination therapy consisting of bevacizumab, doxorubicin and carboplatin was initiated. After six cycles of this combination therapy, the patient exhibited disease stabilization. Finally, 18 months after the initial bevacizumab treatment, the patient remained on combination chemotherapy, without complaints or signs of tumor progression (last follow‑up, October 2014).

Related Articles

Journal Cover

September 2017
Volume 7 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Sato, E., Nakayama, K., Nakamura, K., Ishibashi, T., Katagiri, H., Ishikawa, M., & Kyo, S. (2017). Bevacizumab plus chemotherapy continued beyond progression in patients with type II endometrial cancer previously treated with bevacizumab plus chemotherapy: A case report. Molecular and Clinical Oncology, 7, 391-394. https://doi.org/10.3892/mco.2017.1316
MLA
Sato, E., Nakayama, K., Nakamura, K., Ishibashi, T., Katagiri, H., Ishikawa, M., Kyo, S."Bevacizumab plus chemotherapy continued beyond progression in patients with type II endometrial cancer previously treated with bevacizumab plus chemotherapy: A case report". Molecular and Clinical Oncology 7.3 (2017): 391-394.
Chicago
Sato, E., Nakayama, K., Nakamura, K., Ishibashi, T., Katagiri, H., Ishikawa, M., Kyo, S."Bevacizumab plus chemotherapy continued beyond progression in patients with type II endometrial cancer previously treated with bevacizumab plus chemotherapy: A case report". Molecular and Clinical Oncology 7, no. 3 (2017): 391-394. https://doi.org/10.3892/mco.2017.1316